|
JP2955314B2
(ja)
*
|
1988-10-27 |
1999-10-04 |
リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ |
Ｉｌ―２含有リポソーム免疫アジュバント
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US5536642A
(en)
*
|
1993-09-09 |
1996-07-16 |
Barbera-Guillem; Emilio |
Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
|
|
JPH09506866A
(ja)
*
|
1993-12-14 |
1997-07-08 |
ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン |
医薬として活性のある物質の免疫療法のための放出制御
|
|
US5635597A
(en)
*
|
1994-05-27 |
1997-06-03 |
Affymax Technologies, N.V. |
Peptides that bind IL-2 receptors
|
|
US5696234A
(en)
*
|
1994-08-01 |
1997-12-09 |
Schering Corporation |
Muteins of mammalian cytokine interleukin-13
|
|
US5641665A
(en)
*
|
1994-11-28 |
1997-06-24 |
Vical Incorporated |
Plasmids suitable for IL-2 expression
|
|
US6045788A
(en)
*
|
1996-02-28 |
2000-04-04 |
Cornell Research Foundation, Inc. |
Method of stimulation of immune response with low doses of IL-2
|
|
US6509313B1
(en)
|
1996-02-28 |
2003-01-21 |
Cornell Research Foundation, Inc. |
Stimulation of immune response with low doses of cytokines
|
|
US6790604B1
(en)
|
1998-05-12 |
2004-09-14 |
Stefan A. Cohen |
Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
JP2003530838A
(ja)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
|
EP1401477A4
(de)
*
|
2001-05-25 |
2005-02-02 |
Human Genome Sciences |
Chemokin-beta-1-fusionsproteine
|
|
CA2456470A1
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
|
ES2425738T3
(es)
|
2001-12-21 |
2013-10-17 |
Human Genome Sciences, Inc. |
Proteínas de fusión de la albúmina
|
|
EP1594530A4
(de)
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
Albuminfusionsproteine
|
|
JP2004256444A
(ja)
*
|
2003-02-26 |
2004-09-16 |
Kansai Tlo Kk |
悪性腫瘍の治療方法
|
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
|
CA2678736A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Transgene S.A. |
Novel multifunctional il-2 - il-18 fusion proteins
|
|
ES2333971T3
(es)
|
2003-11-04 |
2010-03-03 |
Novartis Vaccines And Diagnostics, Inc. |
Anticuerpos monoclonales anti-cd40 antagonistas y procedimientos para su uso.
|
|
US20060234205A1
(en)
*
|
2004-03-05 |
2006-10-19 |
Chiron Corporation |
In vitro test system for predicting patient tolerability of therapeutic agents
|
|
WO2006072625A2
(en)
|
2005-01-06 |
2006-07-13 |
Novo Nordisk A/S |
Anti-kir combination treatments and methods
|
|
US7334361B2
(en)
*
|
2005-03-29 |
2008-02-26 |
Adaptive Micro Systems Llc |
Access system for a display panel assembly
|
|
US20110274650A1
(en)
|
2009-01-21 |
2011-11-10 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
BR112013019083A2
(pt)
|
2011-02-10 |
2017-04-04 |
Roche Glycart Ag |
combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
|
|
JP5878182B2
(ja)
|
2011-02-10 |
2016-03-08 |
ロシュ グリクアート アーゲー |
ミュータントインターロイキン−２ポリペプチド
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
JP6175428B2
(ja)
|
2011-06-01 |
2017-08-02 |
イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ |
細菌のポリシストロン性発現系
|
|
US20130064811A1
(en)
*
|
2011-09-09 |
2013-03-14 |
International Business Machines Corporation |
Methods to Enhance Cancer Treatment
|
|
ES2700978T3
(es)
|
2012-08-07 |
2019-02-20 |
Roche Glycart Ag |
Composición que comprende dos anticuerpos genomanipulados para que tengan una función efectora reducida e incrementada
|
|
US10544187B2
(en)
|
2013-03-15 |
2020-01-28 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
EP3110429A4
(de)
|
2014-02-27 |
2018-02-21 |
Lycera Corporation |
Adoptive zelltherapie unter verwendung eines agonisten des retinsäurenrezeptor-assoziierten orphanrezeptors gamma und dazugehörige therapeutische verfahren
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
EP3209641A4
(de)
|
2014-05-05 |
2018-06-06 |
Lycera Corporation |
Benzolsulfonamid und verwandte verbindungen zur verwendung als ror-agonisten und behandlung von erkrankungen
|
|
CA2947290A1
(en)
|
2014-05-05 |
2015-11-12 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
|
CA2963602A1
(en)
|
2014-10-09 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable il-2 dose regimen for treating immune disorders
|
|
CA2982847A1
(en)
|
2015-05-05 |
2016-11-10 |
Lycera Corporation |
Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
|
|
CN107980042B
(zh)
|
2015-06-11 |
2021-10-08 |
莱斯拉公司 |
用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
|
|
MX2018005229A
(es)
|
2015-12-09 |
2019-04-29 |
F HoffmannLa Roche Ag |
Anticuerpo anti-cd20 de tipo ii y usos del mismo.
|
|
EP3178848A1
(de)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
|
|
EP3402499B1
(de)
|
2016-01-14 |
2021-07-21 |
Intrexon Actobiotics NV |
Zusammensetzungen und verfahren zur behandlung von typ-1-diabetes
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2017220989A1
(en)
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Anti-pd-l1 and il-2 cytokines
|
|
WO2018073365A1
(en)
|
2016-10-19 |
2018-04-26 |
F. Hoffmann-La Roche Ag |
Method for producing an immunoconjugate
|
|
EP3534947A1
(de)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
|
|
EP3596108A4
(de)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
Gezielte immuntoleranz
|
|
EP3606947B1
(de)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunokonjugat von il-2 mit einem bispezifischen antikörper gerichtet gegen pd-1 und tim-3
|
|
CA3053357A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
MY206158A
(en)
*
|
2017-05-24 |
2024-12-02 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
BR112019024127A2
(pt)
|
2017-05-24 |
2020-06-23 |
Pandion Therapeutics, Inc. |
Imunotolerância alvejada
|
|
CN111051512A
(zh)
|
2017-07-11 |
2020-04-21 |
辛索克斯公司 |
非天然核苷酸的掺入及其方法
|
|
CN111183149A
(zh)
|
2017-08-03 |
2020-05-19 |
辛索克斯公司 |
用于治疗自身免疫疾病的细胞因子缀合物
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
EP3762406A2
(de)
|
2018-03-09 |
2021-01-13 |
Askgene Pharma, Inc. |
Zytokin-prodrugs
|
|
EP3810185A4
(de)
|
2018-06-22 |
2022-03-23 |
Cugene Inc. |
Interleukin-2-varianten und verfahren zur verwendung davon
|
|
EP3810640A1
(de)
|
2018-06-25 |
2021-04-28 |
University of Washington |
De-novo-design von potenten und selektiven interleukin mimetika
|
|
AU2019343850B2
(en)
|
2018-09-17 |
2024-06-06 |
Gi Innovation, Inc. |
Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
|
|
CN112912388A
(zh)
|
2018-11-20 |
2021-06-04 |
华盛顿大学 |
分拆白介素模拟物和它们的用途
|
|
WO2020127369A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional molecule directed against human pd-1
|
|
WO2020163532A1
(en)
|
2019-02-06 |
2020-08-13 |
Synthorx, Inc. |
Il-2 conjugates and methods of use thereof
|
|
CN111944036B
(zh)
|
2019-05-14 |
2024-09-06 |
上海盖浦生物科技有限公司 |
一种增殖免疫细胞的突变体蛋白
|
|
US11739146B2
(en)
|
2019-05-20 |
2023-08-29 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
SG11202111409YA
(en)
|
2019-05-20 |
2021-12-30 |
Cytune Pharma |
IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
|
|
AU2020291012B2
(en)
|
2019-06-12 |
2025-09-25 |
AskGene Pharma, Inc. |
Novel IL-15 prodrugs and methods of use thereof
|
|
EP3994169A1
(de)
|
2019-07-02 |
2022-05-11 |
F. Hoffmann-La Roche AG |
Immunokonjugate mit einem mutierten interleukin-2 und einen anti-cd8-antikörper
|
|
KR20220051177A
(ko)
|
2019-07-26 |
2022-04-26 |
비스테라, 인크. |
인터류킨-2 작용제 및 이의 용도
|
|
US20220340621A1
(en)
|
2019-09-27 |
2022-10-27 |
Intrexon Actobiotics Nv D/B/A Precigen Actobio |
Treatment of celiac disease
|
|
KR102400884B1
(ko)
|
2019-11-15 |
2022-05-23 |
주식회사 제넥신 |
변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도
|
|
CA3157592A1
(en)
|
2019-11-20 |
2021-05-27 |
Myoung Ho Jang |
Composition for culturing natural killer cells and method for preparing natural killer cells by using same
|
|
CN114901807B
(zh)
|
2019-11-20 |
2023-07-11 |
吉爱希公司 |
调节性t细胞培养组合物及其用途
|
|
IL292934A
(en)
|
2019-11-20 |
2022-07-01 |
Gi Cell Inc |
Medium composition for culturing t cells and method for culturing t cells using same
|
|
AU2020392166A1
(en)
|
2019-11-27 |
2022-05-26 |
Gi Innovation, Inc. |
Pharmaceutical composition for treatment of cancer, comprising immune checkpoint inhibitor and fusion protein including IL-2 protein and CD80 protein
|
|
BR112022010063A2
(pt)
*
|
2019-11-27 |
2022-09-06 |
Gi Cell Inc |
Composição para tratamento anticâncer, compreendendo células nk e proteína de fusão que compreende proteína il-2 e proteína cd80
|
|
WO2021168079A1
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
|
US11857601B2
(en)
|
2020-03-18 |
2024-01-02 |
Gi Innovation, Inc. |
Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug
|
|
US20230139890A1
(en)
|
2020-03-18 |
2023-05-04 |
Gi Innovation, Inc. |
Fusion protein comprising il-2 protein and cd80 protein fragment or variant thereof, and uses thereof
|
|
US20230125871A1
(en)
|
2020-03-18 |
2023-04-27 |
Gi Innovation, Inc. |
Fusion protein preparation comprising il-2 and cd80 proteins
|
|
CR20220530A
(es)
|
2020-04-22 |
2022-12-15 |
Merck Sharp & Dohme Llc |
CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 ß¿c Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO.
|
|
KR102373965B1
(ko)
|
2020-06-05 |
2022-03-15 |
(주)지아이이노베이션 |
Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
|
|
EP4174088A4
(de)
|
2020-06-30 |
2024-01-24 |
GI Innovation, Inc. |
Fusionsprotein mit anti-lag-3-antikörper und il-2 sowie verwendung davon
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
CA3195276A1
(en)
|
2020-10-26 |
2022-05-05 |
Stefano FERRARA |
Il-2/il-15rb?? agonist for treating non-melanoma skin cancer
|
|
WO2022090203A1
(en)
|
2020-10-26 |
2022-05-05 |
Cytune Pharma |
IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
|
|
US12098178B2
(en)
|
2020-12-04 |
2024-09-24 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
US20240092853A1
(en)
|
2020-12-04 |
2024-03-21 |
Hoffmann-La Roche Inc. |
Ph-dependent mutant interleukin-2 polypeptides
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
IL305847A
(en)
|
2021-03-26 |
2023-11-01 |
Innate Pharma |
Multispecific proteins that contain a binding site for NKP46, a binding site for a cancer antigen that is fused to a cytokine to attract NK cells
|
|
EP4314032A1
(de)
|
2021-03-30 |
2024-02-07 |
F. Hoffmann-La Roche AG |
Protease-aktivierte polypeptide
|
|
MX2023011964A
(es)
|
2021-04-09 |
2024-01-08 |
Ose Immunotherapeutics |
Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
|
|
CN115867645A
(zh)
|
2021-05-18 |
2023-03-28 |
赛斯尔擎生物技术（上海）有限公司 |
修饰细胞的方法
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
MX2023014647A
(es)
|
2021-06-09 |
2024-01-31 |
Innate Pharma |
Proteinas de union a nkp46 multiespecificas.
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
CN117529504A
(zh)
|
2021-06-09 |
2024-02-06 |
先天制药公司 |
结合至cd20、nkp46、cd16并缀合至il-2的多特异性抗体
|
|
WO2022266467A2
(en)
|
2021-06-17 |
2022-12-22 |
Dana-Farber Cancer Institute, Inc. |
Recombinant histone polypeptide and uses thereof
|
|
WO2023017191A1
(en)
|
2021-08-13 |
2023-02-16 |
Cytune Pharma |
Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
|
|
WO2023249425A1
(ko)
*
|
2022-06-22 |
2023-12-28 |
㈜지아이이노베이션 |
항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
|
|
EP4594345A1
(de)
|
2022-09-29 |
2025-08-06 |
F. Hoffmann-La Roche AG |
Protease-aktivierte polypeptide
|
|
WO2024119193A2
(en)
|
2022-12-02 |
2024-06-06 |
AskGene Pharma, Inc. |
Mutant il-2 polypeptides and il-2 prodrugs
|
|
KR20250135861A
(ko)
|
2023-01-20 |
2025-09-15 |
에프. 호프만-라 로슈 아게 |
재조합 Fc 도메인 - IL2 변이체 폴리펩타이드 및 막 고정 항원 결합 폴리펩타이드와의 조합 요법
|
|
WO2024215989A1
(en)
|
2023-04-14 |
2024-10-17 |
Sotio Biotech Inc. |
ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
|
|
WO2024251884A1
(en)
|
2023-06-09 |
2024-12-12 |
Innate Pharma |
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
|